Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | DUSP4 | Q13115 | 1/20 | 0.36 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320187 | 0.82 | KDM4E (0.47) | METAP2NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL11160532 | 0.78 | PDGFRB (0.38) | CYP2A6PDGFRBPDGFRACYP3A4PIK3CA | |
| SCHEMBL5619122 | 0.78 | CYP1A2 (0.35) | CYP2A6PDGFRBPDGFRAPIK3CACYP1A2 | |
| SCHEMBL2659111 | 0.78 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL1385432 | 0.75 | ALDH1A1 (0.42) | CYP2A6PDGFRBPDGFRACYP3A4NPC1 | |
| SCHEMBL16268045 | 0.74 | METAP2 (0.46) | METAP2CYP3A4PIK3CADUSP4PTP4A1 | |
| SCHEMBL15229223 | 0.74 | ALDH1A1 (0.43) | PDGFRBPDGFRACYP3A4NPC1RAB9A | |
| SCHEMBL523809 | 0.73 | RAB9A (0.44) | CYP3A4NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL7914703 | 0.73 | PDGFRB (0.50) | CYP2A6PDGFRBPDGFRACYP3A4NPC1 | |
| SCHEMBL1542711 | 0.73 | DHODH (0.39) | CYP2A6NPC1RAB9AALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | claimed |
| EP-3743430-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-12-02 | — | — | EP | claimed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | claimed |
| WO-2019147782-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | WO | claimed |
| EP-2812323-A1 | TETRAHYDRO-QUINAZOLINONE DERIVATIVES AS TANK AND PARP INHIBITORS | Merck Patent GmbH (DE) | 2014-12-17 | — | — | EP | claimed |
| WO-2013117288-A1 | TETRAHYDRO-QUINAZOLINONE DERIVATIVES AS TANK AND PARP INHIBITORS | MERCK PATENT GMBH (DE) | 2013-08-15 | — | — | WO | claimed |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
| EP-3743430-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| WO-2019147782-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | WO | disclosed |
| US-20150152126-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2015-06-04 | — | — | US | disclosed |
| EP-2609100-A2 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | METAP2 1349/4885CYP2A6 4384/4885PDGFRB 3168/4885 |
| US-20150152126-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | METAP2 1689/4885CYP2A6 3470/4885PDGFRB 884/4885 |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | RIPK1, RIPK2, RIPK4 | METAP2 1349/4885CYP2A6 4384/4885PDGFRB 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.